Analyst initiations: WX, AAPL and DNA
Posted Jun 19th 2008 10:50AM by Eric Buscemi
Filed under: Analyst Reports, Genentech Inc (DNA), Analyst Initiations
.gif)
MOST NOTEWORTHY: WuXi Pharma, Apple and Genentech were today's noteworthy initiations:
- Global Hunter expects WuXi Pharma (NYSE:WX) to remain under pressure in the near-term due to gross margin constraints and dilution risk from the AppTec acquisition. The firm finds the stock fairly valued at current levels and initiated shares with a Neutral rating.
- ThinkPanmure assumed Apple (NASDAQ:AAPL) with a Buy rating and $225 target and recommends investors take advantage of recent weakness to build core positions.
- Genentech (NYSE:DNA) was started at Deutsche Bank with a Buy rating and $83 target. The firm sees limited downside and the potential for significant upside if Avastin works in adjuvant colon cancer.
OTHER INITIATIONS:
- NetLogic (NASDAQ:NETL) was initiated with a Neutral rating and $36 target at Piper.
- UBS assumed Seattle Genetics (NASDAQ:SGEN) with a Neutral rating and $10 target.
- Rowan Companies (NYSE:RDC) was started with a Buy rating and $70 target at Jesup & Lamont.
Tags: AAPL, analyst initiations, AnalystInitiations, DNA, NETL, RDC, SGEN, WX
Tax Reform in This Election Year: It's Not Likely
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
